About Greg Tietjen

Human-First Drug Development and Replacing Animal Models

Greg Tietjen champions a paradigm shift from animal models to human organs and data trials, arguing they better predict human responses and align with FDA's human-first framework.[3][6][16][23] At Revalia Bio, his platform uses donated human organs unsuitable for transplant to test drugs, enabling 'catalytic failure'—deliberate early identification of ineffective candidates to streamline development.[9][16] This addresses the 90%+ clinical failure rate by generating human-specific toxicology data.[1][11]

Data Integrity and Ethics

Tietjen views data integrity as an ethical obligation beyond science, especially with human data, to prevent harm and ensure trust in biomedical innovation.[8][13][19] Co-authored with Jenna DiRito, his work stresses rigorous standards in human-centered models.[15]

AI and Technology in Clinical Settings

He predicts 'no limits' on AI in clinical settings by 2026, particularly for toxicology and human data analysis, accelerating safety assessments.[1] Advanced data systems paired with human models unlock breakthroughs.[7]

Entrepreneurship and Leaving Academia

Tietjen left a successful academic career mid-stream, likening his path to a jazz musician riffing on opportunities.[12] He co-founded Revalia Bio, raising $14.5M in seed funding to launch the human data trial platform, backed by Yale and investors.[20][21][22] His venture revolutionizes drug development commercialization.[9][10]

Background and Affiliations

A molecular biophysics expert and former Yale Assistant Professor, Tietjen advanced organ transplant viability.[5][11][14] He consults, speaks globally (TED Fellow 2026[17], C-Path[4], Longwood[10]), and collaborates long-term with experts like Jenna DiRito.[2]

Music/Arts Influence

Tietjen lives 'like a jazz musician,' using improvisation to bridge science, business, and innovation across his multifaceted career.[12]